Just last month, Glenmark's wholly owned subsidiary Ichnos Glenmark Innovation Inc (IGI) had signed a licencing agreement with US drugmaker AbbVie for IGI's lead drug candidate ISB 2001, for an upfront payment of $700 million (estimated ₹6,000 crore). The drug candidate had shown promising outcomes in patients with relapsed / refractory multiple myeloma, during Phase I clinical trials.